Antifibrinolytic Wound Dressing for Exudate Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current wound treatment methods struggle with effectively managing exudate production in wounds such as skin graft donor sites and scald injuries, leading to painful dressing changes and delayed healing.
Innovation Solution
A wound dressing incorporating a therapeutically effective amount of antifibrinolytic agents like tranexamic acid (TXA) is applied to reduce exudate generation and promote healing, potentially eliminating the need for repeated dressing changes and drainage devices.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If traditional wound dressings are used without antifibrinolytic agents, then the wound can be treated with simple dressings, but the wound produces large amounts of exudate requiring repeated dressing changes and drainage devices
Solution Approach 1:
The antifibrinolytic agent is applied to the wound bed before the dressing is placed, pre-treating the wound to reduce exudate production. This preliminary action modifies the wound environment so that when the dressing is applied, exudate generation is already diminished, eliminating the need for complex drainage systems.
Solution Approach 2:
The antifibrinolytic agent acts as an intermediary substance between the wound bed and the dressing. It modifies the wound exudate characteristics by inhibiting fibrinolysis, thereby reducing the quantity and potentially the composition of exudate that would otherwise require complex management systems.
2Quantity of substance
If repeated dressing changes are performed to manage exudate, then exudate can be removed, but the treatment becomes painful and time-consuming
Solution Approach 1:
By applying the antifibrinolytic agent before dressing placement, the exudate production is reduced in advance. This preliminary modification of wound physiology allows a single dressing to remain effective throughout the entire healing process, eliminating the need for repeated dressing changes and associated time loss.
Solution Approach 2:
The antifibrinolytic agent provides continuous action throughout the healing process, maintaining reduced exudate production from the initial application through to wound closure. This continuous therapeutic effect ensures that a single dressing application remains effective throughout the entire treatment period.
3Quantity of substance
If antifibrinolytic agents are used to reduce exudate, then exudate production is significantly reduced, but the agents have side effects and risk for allergic response
Solution Approach 1:
The antifibrinolytic agent is applied as a disposable, single-use treatment in the form of a soaked sponge or dressing that is removed after one use. This approach delivers the therapeutic benefit of reduced exudate production while limiting the duration of exposure to potential side effects, as the agent is not continuously present in the system.
Solution Approach 2:
The agent is applied preliminarily and then removed after serving its purpose of reducing initial exudate production. This temporary, controlled exposure minimizes the risk of allergic responses and side effects while still achieving the therapeutic goal of reduced exudate during the critical initial healing phase.
4Quantity of substance
If drains are used to manage exudate, then exudate can be continuously removed, but the treatment requires ongoing drainage and may result in delayed healing
Solution Approach 1:
The invention extracts the need for continuous drainage systems by using the antifibrinolytic agent to fundamentally reduce exudate production at its source. By modifying the wound's physiological response, the treatment removes the requirement for ongoing mechanical exudate removal and extends the effective action period beyond what drains can provide.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of TXA in wound dressings significantly reduces exudate production, allowing for a single dressing application that can last throughout the healing process without extending re-epithelialization time, thus improving wound healing outcomes.
Implementation Method 1
The therapeutic agent can comprise a therapeutically effective amount of antifibrinolytic agent such as tranexamic acid (TXA) that serves both as a hemostat and is operative to reduce the generation of sanguineous and/or serous exudate from the wound
Implementation Method 2
The amount of exudate is substantially reduced to a level that is less than the absorption capacity of the wound dressing
Data Source
AI summary
Device and methods for treating wounds or surgical sites are provided. The devices and methods include use of antifibrinolytic agents such as tranexamic acid to reduce exudate and improve wound healing. Embodiments provide for the timed release of therapeutic agents from wound dressings to extend a delivery time through the inflammatory phase of wound healing.